# US 11,077,080 B2 · Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,077,080 B2
- Document ID: US11077080B2
- Status: Granted
- Kind: B2
- Application number: 14/736,004
- Filed: 2015-06-10
- Published: 2015-10-01
- Granted: 2021-08-03
- Earliest claimed: 2008-09-10
- Assignees: Commissariat A L'energie Atomique Aux Energies Alternatives; Bio Modeling Systems Ou Bmsystems
- Applicants: Commissariat A L'Energie Atomique Et Aux Energies Alternatives; Bio Modeling Systems Ou Bmsystems
- Inventors: Franck Mouthon; Mathieu Charveriat; Jean-Philippe Deslys; François Iris
- Web page: https://patentgrep.com/patent/US11077080B2

## CPC

- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-β-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid. The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-β-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid.

## Claims

### Claim 1

Method for treating patients suffering from one or more of depression; bipolar disorder; schizophrenia; anxiety; stress; panic; phobias; obsessive compulsive disorders; behavioral disorders; pain; fibromyalgia; eating disorders selected from the group consisting of bulimia and anorexia; migraine; and neurodegenerative disorders selected from the group consisting of Alzheimer's disease, Huntington's disease and Parkinson's disease, comprising the administration to said patients of:
a) at least one psychotropic drug; and
b) at least one connexin-blocking agent;
the drug a) and the agent b) are administrated simultaneously, separately or spread out over time;
wherein the at least one psychotropic drug is a serotoninergic effector selected from the group consisting of chlorpromazine, trimipramine, clozapine, olanzapine, cyamemazine, flupentixol, nefopam, fluvoxamine, clomipramine, sertraline, fluoxetine, citalopram, escitalopram, paroxetine, amitriptyline, duloxetine, venlafaxine, buspirone, carpipramine, zolmitriptan, sumatriptan, naratriptan, indoramine, ergotamine, ergotamine tartrate, pizotifene, pipamperone, methysergide, pizotyline, tianeptine, milnacipran, amitriptylene, trimipramine, viloxazine, tianeptine, hypericum, lithium, and combinations thereof,
wherein the at least one connexin-blocking agent is selected from the group consisting of meclofenamic acid, 18-β-glycyrrhetinic acid, mefloquine, 2-APB and combinations thereof,
wherein the at least one connexin-blocking agent is administered at a dose at least 10 to 25-fold less than a dose having an anti-inflammatory effect.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the serotoninergic effector is amitriptyline.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the serotoninergic effector is amitriptyline and the connexin-blocking agent is mefloquine.